A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib
Read time: 1 mins
Last updated:4th Dec 2012
The purpose of this study is to determine the rate of successful treatment-free remission (TFR) within the first 12 months following cessation of treatment in patients who achieved and maintained a molecular response (MR) 4.5 on nilotinib after a switch from imatinib. TFR phase is often referred to as discontinuation phase in other studies.
|Study start date||2012-12-04|